Please assess the completion status of the following clinical trial:

Trial Title: Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is 18 through 70 years of age.~* Patient has moderate to severe non-malignant chronic pain.~* Patient is opioid-tolerant, requires treatment with chronic opioids and is currently taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain. Patient must have been taking this dose for at least 2 weeks.~* Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough pain that is related to the patient's chronic pain condition) a day while taking a dose of 50 mcg/hr transdermal fentanyl.~Exclusion Criteria:~* Patient has active cancer.~* Patient has a history of substance abuse or has a substance abuse disorder.~* Patient is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 50 mcg/hr matrix fentanyl patch (Type: EXPERIMENTAL): active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
- Placebo Patch (Type: PLACEBO_COMPARATOR): placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch

Based on this trial design, predict the completion outcome and termination type (if applicable).